divestiture

Rosetta acquired PersonalizeDx and its range of molecular diagnostic offerings in early 2015 for $2 million in cash plus stock.

Hologic's CEO said in December that the blood screening business was a drag on the company's growth. 

The company said the divestiture to Varian Medical Systems would allow it to concentrate on investing in high-growth parts of its business.

Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.

The company said it earned approximately $128 million in revenue in 2015, and accessioned 42,000 total commercial diagnostic test samples.

The moves are part of an organizational restructuring designed to increase the company's focus on its core women's health business and reduce operating costs.

Transgenomic has completed its divestment of its Genetic Assays and Platforms unit to Adstec

PDI also said that it would assume the name of its subsidiary, Interpace Diagnostics, to better reflect its focus on its molecular diagnostic operations.

The company sold the technology and assets to Edge BioSystems as part of an ongoing effort to divest legacy non-core businesses and product lines.

NEW YORK (GenomeWeb) – Saying that it does not believe its Chemical and Applied Markets division can achieve "acceptable financial performance" in the next two years, Bruker today said that it plans to sell and/or restructure certain parts of the CAM business, resulting in an expected 200 to 250

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.